EP-1231: Comparison of cone beam CT imaging protocols in imageguided radiotherapy for prostate cancer  by Ariyaratne, H. et al.
S666                                                                                                                                         3rd ESTRO Forum 2015 
 
suboptimal repair of RT-induced damages to local blood cells 
circulating in the pelvis during irradiation (RT) and reduced 
pelvic hematopoiesis. 
Materials and Methods: In 2012 a prospective, observational, 
study evaluating hematologic and urinary toxicity after 
whole-pelvis radiotherapy (WPRT) was activated. For the 
study purposes, the International Prostate Symptoms Score 
questionnaire (IPSSq) has to be filled by pts and a blood 
sample has to be obtained at baseline, at RT mid-point and 
end, and after 3, 6, 12, 18, 24, 30 and 36 months. RT was 
delivered with static-field IMRT, Tomotherapy and VMAT in 
17, 23 and 34 pts, respectively, at conventional fractionation 
(CF, 1.8-2 Gy) in 24 and with moderate hypofractionation 
(HYPO, median 2.35 Gy/fraction) in 50. WPRT was delivered 
at up to 50.4 Gy/28 fractions in CF and at 52.50 Gy/30 
fractions in HYPO. The median variation (delta, Δ) of 
absolute lymphocyte count at given time over baseline (Δ 
ALC) was calculated. 
Results: For 74 pts both baseline and one year IPSSq were 
collected, for 69 blood samples were taken at baseline and 
RT midpoint and end, for 66, 67 and 71 pts also at 3, 6 and 12 
months, respectively. The median ΔALC at RT mid-point and 
end, and at 3, 6 and 12 months after WPRT completion was 
35%, 30%, 45%, 50% and 54%, respectively. A borderline 
association between ΔALCs and ΔIPSS at 12 months was found 
(Mann-Whitney test: p-values 0.056-0.09). Unexpectedly, by 
setting the event for logistic regression analysis as the 75th 
percentile of 12 months ΔIPSS (ΔIPSS12, ≥4), the mean ΔALC 
was always higher in pts with late UT when compared to pts 
without UT (Figure 1). Variables with a p-value <0.10 at 
univariate analysis (i.e. time from prostatectomy to RT, 
volume of lymph-nodal irradiated area and ΔALC at RT mid-
point and 6 months), were entered into a multivariable Cox 
model which confirmed an independent role for ΔALC at 6 
months (OR 3.52, p=0.02) in predicting worsening of IPSS at 
1-year. 
 
 
Conclusions: These results indicate that pts with reduced RT-
induced lymphopenia are at higher risk for UT when 
compared to more lymphopenic patients. Given the notion 
that RT favours leukocyte extravasation (Vianello et al. Br J 
Hemat 2013), we postulate that late UT may be caused, at 
least in part, by tissue-infiltrating leukocytes able to 
propagate local inflammation and more pronounced fibrotic 
processes in the late regenerative phase, one of the possible 
main causes for the onset of late UT following RT.  
These data provide rationale for addressing changes of 
inflammatory markers during/after RT and support the use of 
ΔALC as predictive of UT. 
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Purpose/Objective: To assess the effects of verification 
imaging protocol on the actual doses delivered to the target 
volume and organs at risk during a course of image-guided 
radiotherapy (IGRT) for prostate cancer. 
Materials and Methods: 844 cone-beam CT (CBCT) 
verification images from 20 patients undergoing radical 
prostate radiotherapy were analysed. All patients received a 
dose of 74 Gy in 37 fractions using 7-field intensity-
modulated radiotherapy (IMRT). During treatment, patients 
had daily online CBCT soft tissue match verification using the 
Elekta XVI system. Early toxicity was assessed using the RTOG 
acute radiation morbidity scale. All CBCT images were 
imported into the Pinnacle treatment planning system. 
Target volume and organs at risk were contoured manually on 
each CBCT image. A 7 mm margin in all directions was used 
around the clinical target volume (CTV) to obtain the 
planning target volume (PTV). Soft tissue match shifts were 
separately applied to each CBCT image. The CBCT contours 
were superimposed on the planning CT scan for dose-volume 
analysis. Dose-volume parameters were assessed for the PTV, 
CTV, rectum and bladder. The same contours were used for 
comparison of a daily online schedule with a protocol of day 
1-3 followed by weekly imaging. A further comparison was 
carried out between online and offline weekly verification 
schedules. Paired t test and Wilcoxon signed rank test were 
used to compare parametric and non-parametric dosimetric 
statistics. 
Results: 90% of patients had improvement in prostate target 
coverage with daily online imaging in comparison to weekly 
online imaging, with statistically significant benefits in 
dosimetric parameters assessed (Table 1). Daily online 
imaging was the best verification protocol, with a median of 
37 fractions (out of 37) achieving CTV coverage with daily 
imaging compared with 33 and 34 fractions respectively with 
weekly offline and weekly online protocols (Fig. 1). There 
were low levels of acute toxicity in the patient population 
when daily imaging was used. On dosimetric analysis, 80% of 
patients had a reduction in rectal dose with the daily imaging 
protocol. On average, there was a 1.13 Gy reduction in mean 
rectal dose, which would mitigate the concomitant dose to 
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pelvis from imaging. There were no significant differences in 
bladder dose. The magnitude of benefit of daily imaging for a 
patient could not be predicted by characteristics on planning 
CT scan. 
 
Conclusions: Daily online CBCT verification imaging improves 
CTV coverage and reduces dose to rectum during IGRT for 
prostate cancer.  
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Purpose/Objective: This study aimed to investigate the 
impact of increasing radiation delivery time on the outcome 
of hypofractionated radiation therapy for prostate cancer. 
Intrafraction repair is seldom discussed in relation to external 
beam radiation therapy as most fractional doses are 
delivered in the course of a few minutes and the beam-on 
time is not very much different from the time to deliver all 
individual fields. Advanced techniques aimed at delivering 
high fractional dose, employing multiple fields, scanning the 
target volume or requiring multiple imaging sessions may 
however take considerably longer, increasing the importance 
of intrafraction repair. 
Materials and Methods: Mono-exponential and bi-exponential 
repair models have been used in prostate patients to study 
the loss of biologically effective dose for several clinically-
relevant irradiation times between 5 and 60 minutes. These 
were then converted into loss of biochemical control at 5 
years using clinically-relevant dose response curves derived 
from 10688 prostate patients treated with conventional 
fractionation. The theoretical predictions were subsequently 
compared with clinical results from 14 newly reported studies 
totalling 4363 patients undergoing conventionally-
fractionated and hypofractionated prostate radiotherapy. 
Results: For low-risk patients the equivalent doses delivered 
were quite high and consequently the reported results were 
very good and in agreement with theoretical predictions. For 
intermediate- and high-risk patients however, the results 
from hypofractionated schedules delivered with time-
consuming techniques appear to be compatible with 
predictions accounting for intrafraction repair taking place 
during longer irradiations, while results from moderately 
hypofractionated or conventionally-fractionated schedules 
are in agreement with short irradiation times. Treatment 
sessions lasting more than about 20 minutes could lead to 
significant loss of biochemical control even when relatively 
slow repair is relevant for prostate tumours. Large effect 
losses could therefore be expected from extremely 
hypofractionated schedules with long irradiation sessions as 
might be the case of scanned beams and/or with multiple 
intrafraction imaging sessions to check the positioning of the 
patient. The loss of effect might also be reflected into an 
apparent reduced sensitivity to fractionation for the tumours. 
Conclusions: Intrafraction repair plays an important role for 
prostate radiation therapy and may lead to loss of biological 
effect in the case of extremely hypofractionated techniques 
requiring increased irradiation times Neglecting intrafraction 
could also interfere with the derivation of the fractionation 
sensitivity for prostate tumours.  
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Purpose/Objective: To test the hypothesis that implantation 
of a hydrogel rectum spacer in patients with prostate cancer 
undergoing intensity modulated radiation therapy (IMRT) 
reduces predicted probabilities for grade 2-3 (Gr2-3) acute 
and late rectal toxicities. 
Materials and Methods: In 26 patients with localized prostate 
cancer (low-risk:8/26(31%); intermediate-risk: 11/26 (42%); 
high-risk: 7/26 (27%)), a hydrogel spacer (SpaceOAR®, 
Augmenix) was injected under transrectal ultrasound 
guidance in Denonvilliers’ space between the prostate and 
the rectal wall. IMRT treatment plans (78 Gy in 39 fractions) 
were designed based on CT scans acquired before (IMRT-pre) 
and after (IMRT-post) hydrogel injection. Published 
nomograms based on clinical risk factors (use of 
anticoagulantia, hormonal therapy, and anti-hypertensives, 
presence of diabetes, haemorrhoids, pre-EBRT abdominal 
surgery) and dose-volume histogram (DVH) parameters (V40Gy, 
V75Gy) were used to estimate predicted probabilities for Gr2-3 
acute gastro-intestinal (GI) toxicity1, Gr2-3 late rectal 
bleeding (LRB)2, and Gr2-3 fecal incontinence (FI)2 for IMRT-
